Image via Wikipedia
For patients who suffer a major heart attack, get treatment at the hospital but are left with a damaged heart, Dr. Roger Gammon of the Heart Hospital of Austin is testing a new process to reverse that damage.
Just as a Houston hospital is investigating stem cells to repair the brains of stroke patients (see yesterday’s blog), the Heart Hospital is trying out a new stem cell therapy to fix the hearts of patients who suffered their first attack.
It is one of the nation’s first hospitals to test the new therapy.
Gammon, an interventional cardiologist, is leading the clinical
A first-of-its-kind study is just getting underway at University of Minnesota Physicians Heart at Fairview, in Minneapolis. The FDA-approved trial is designed to test the impact of stem cells on restoring the heart’s muscle function in patients suffering from advanced heart failure. The results of the trial could impact the future of health care in the area of heart disease, and may one day save lives (…)
“This trial is designed for heart failure patients in the end stage of heart failure, with no options for treatment,” explained Ganesh Raveendran, M.D., who is the principal investigator of the clinical trial.
New research has found that stem cells derived from human cord blood could be an effective alternative in repairing heart attacks.
At least 20 million people survive heart attacks and strokes every year, according to World Health Organisation estimates, but many have poor life expectancy and require continual costly clinical care. The use of patient’s own stem cells may repair heart attacks, although their benefit may be limited due to scarce availability and ageing. The researchers have found heart muscle-like cells grown using stem cells from human umbilical cord blood could help repair heart muscle cells damaged by a heart
Adipose Stem Cell Heart Attack Trial Data Published in Journal of the American College of Cardiology; Cytori’s APOLLO Trial Demonstrated Safety & Feasibility and Improvements in Cardiac Function
Cytori Therapeutics announced today the publication of previously reported six-month outcomes from APOLLO, the Company’s European clinical trial evaluating adipose-derived stem and regenerative cells (ADRCs) in patients with acute myocardial infarction (heart attack or AMI), as Research Correspondence in the Journal of the American College of Cardiology. The APOLLO trial was a 14-patient, prospective, randomized, double-blind, placebo-controlled, feasibility trial (Phase I/IIA) evaluating autologous ADRCs extracted with the Company’s proprietary Celution® System for
Image via Wikipedia
Treating a heart attack with the patients’ own bone marrow stem cells boosts blood flow within the heart and may help reduce long-term complications, a new U.S. study finds.
The study included 31 patients who underwent angioplasty and stent placement after a heart attack. Within one week of the attacks, 16 of the patients received infusions of their own bone marrow cells into the coronary artery in which a blockage had caused the event.
The 16 patients received different amounts of bone marrow stem cells — 5 million, 10 million and 15 million cells. The 15 patients in the